Edouard J. Trabulsi, MD
Ongoing clinical trials in prostate cancer are adopting multimodal approaches to develop more effective treatments for patients with locally advanced disease, notes Edouard J. Trabulsi, MD. For example, researchers at Thomas Jefferson University Hospital are conducting a trial assessing cabazitaxel (Jevtana) in combination with hormone therapy and radiotherapy in high-risk patients with locally advanced prostate cancer (NCT01420250).
on Prostate Cancer, Trabulsi, professor, co-director, Multidisciplinary Genitourinary Oncology Center, Prostate Diagnostic Center, vice chair of research, director, Division of Urologic Oncology, Department of Urology, Sidney Kimmel Cancer Center, Thomas Jefferson University Hospital, discussed emerging multimodal treatment approaches for patients with locally advanced prostate cancer.
OncLive: You spoke on locally advanced prostate cancer. What are the main points from your presentation?
: I spoke about locally advanced prostate cancer with the intent of defining the meaning of locally advanced disease and how the NCCN guidelines have impacted available treatment options. I also reviewed some of the standard dogmas of treatment and dove into combination and multimodal therapies such as radiation therapy combined with surgery and radiation therapy combined with hormonal therapy.
... to read the full story